Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured

Journal Scan / Research · November 12, 2024

Efficacy and Safety of Trastuzumab Duocarmazine in Pretreated Patients With HER2+ Advanced or Metastatic Breast Cancer

Journal of Clinical Oncology

 

Additional Info

Journal of Clinical Oncology
Trastuzumab Duocarmazine in Pretreated Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Breast Cancer: An Open-Label, Randomized, Phase III Trial (TULIP)
J. Clin. Oncol 2024 Oct 23;[EPub Ahead of Print], N Turner, C Saura, P Aftimos, E van den Tweel, M Oesterholt, N Koper, M Colleoni, E Kaczmarek, K Punie, X Song, A Armstrong, G Bianchi, A Stradella, S Ladoire, JSJ Lim, N Quenel-Tueux, TJ Tan, S Escrivá-de-Romaní, J O'Shaughnessy

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading